Anti-factor Xa monitoring of anticoagulation during cardiopulmonary bypass in a patient with antiphospholipid syndrome.
The activated clotting time (ACT) may be an unreliable monitor of coagulation for patients with the antiphospholipid syndrome. We describe a patient with antiphospholipid syndrome in whom adequate anticoagulation during cardiopulmonary bypass was confirmed by monitoring both the ACT and anti-factor Xa levels. The cardiopulmonary bypass was uneventful, and there were no thrombotic or bleeding complications. The use of anti-factor Xa levels provided confirmation of adequate anticoagulation (and reversal of anticoagulation) that was not possible using the ACT alone.
Lennon
M J
MJ
Department of Anaesthesia, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, W.A. 6009.
Thackray
N M
NM
Gibbs
N M
NM
D000328:Adult; D016736:Antiphospholipid Syndrome / Q000097:blood*; D000990:Antithrombin III / Q000302:isolation & purification*; D001777:Blood Coagulation; D002315:Cardiopulmonary Bypass; D005260:Female; D006801:Humans; D019934:International Normalized Ratio
D000990:Antithrombin III